
    
      No investigational vaccine will be administered in the study. Subjects who were previously
      randomized and completed the primary series, Study A3L24 and the booster study A3L27 will be
      invited to take part in this study.

      Any serious adverse events (SAEs) related to the vaccines administered during the preceding
      trial (A3L27;) and SAEs related to A3L28 study procedures will be collected throughout the
      trial.

      No vaccine will be administered as part of this study.
    
  